Author Interviews, Cancer Research, JAMA, Weight Research / 02.11.2025
GLP-1RA Use May Reduce Risk of Developing Several Obesity-Related Cancers
MedicalResearch.com Interview with:
[caption id="attachment_71229" align="alignleft" width="125"]
Dr. Bian Jiang[/caption]
Jiang Bian, PhD
Associate Dean of Data Science
Walther and Regenstrief Professor of Cancer Informatics
Professor of Biostatistics & Health Data Science
Adjunct Professor, Biomedical Engineering and Informatics
Chief Data Scientist, Regenstrief Institute
Chief Data ScientistCustomize & Schedule Social Media Posts
Indiana University Health
[caption id="attachment_71230" align="alignleft" width="125"]
Dr. Serena Guo[/caption]
Serena Jingchuan Guo, MD PhD
Assistant Professor
Department of Pharmaceutical Outcomes and Policy
University of Florida College of Pharmacy
[caption id="attachment_71231" align="alignleft" width="125"]
Dr. Hao Dai[/caption]
Hao Dai, PhD
Postdoctoral Fellow
Department of Biostatistics & Health Data Science
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users.
We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
Dr. Bian Jiang[/caption]
Jiang Bian, PhD
Associate Dean of Data Science
Walther and Regenstrief Professor of Cancer Informatics
Professor of Biostatistics & Health Data Science
Adjunct Professor, Biomedical Engineering and Informatics
Chief Data Scientist, Regenstrief Institute
Chief Data ScientistCustomize & Schedule Social Media Posts
Indiana University Health
[caption id="attachment_71230" align="alignleft" width="125"]
Dr. Serena Guo[/caption]
Serena Jingchuan Guo, MD PhD
Assistant Professor
Department of Pharmaceutical Outcomes and Policy
University of Florida College of Pharmacy
[caption id="attachment_71231" align="alignleft" width="125"]
Dr. Hao Dai[/caption]
Hao Dai, PhD
Postdoctoral Fellow
Department of Biostatistics & Health Data Science
Indiana University School of Medicine
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Obesity and type 2 diabetes are both known to increase the risk of several cancers. Glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become very popular for both glycemic control and weight loss, but their long-term effects on cancer risk are still unclear. Using a large real-world dataset, we emulated a target trial comparing more than 43,000 GLP-1RA users to matched non-users.
We found that GLP-1RA use was associated with a significantly lower overall cancer risk.
Prof. Mainous[/caption]
Arch G. Mainous III, PhD
Professor
Department of Health Services Research, Management and Policy
Professor and Vice Chair for Research
Department of Community Health and Family Medicine
University of Florida
MedicalResearch.com: What is the background for this study?
Response: We are always concerned about infections from antibiotic resistant bacteria. When the bacteria are resistant to our current treatments this lengthens the time and severity of the illness. Staphylococcus aureus is a major cause of community and healthcare associated infections. These range from skin infections to invasive infections and even death. Methicillin-resistant S. aureus (MRSA) is of particular concern and is a burden on the health care system. Importantly, patients colonized, not infected, with MRSA are more likely to develop MRSA infections and patients with MRSA infections have increased risk of hospital length of stay and even death.
We are always concerned about infections from antibiotic resistant bacteria. When the bacteria are resistant to our current treatments this lengthens the time and severity of the illness. Staphylococcus aureus is a major cause of community and healthcare associated infections. These range from skin infections to invasive infections and even death. Methicillin-resistant S. aureus (MRSA) is of particular concern and is a burden on the health care system. Importantly, patients colonized, not infected, with MRSA are more likely to develop MRSA infections and patients with MRSA infections have increased risk of hospital length of stay and even death.